Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05045027 · ClinicalTrials.gov registry record · Early Phase 1
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
A Early Phase 1 study of Glioma and Malignant Glioma, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05045027 is a Early Phase 1 study of Glioma and Malignant Glioma that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 36 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05045027, a Early Phase 1 study of Glioma and Malignant Glioma, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Diagnostic Imaging
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2027-09-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05045027
The ClinicalTrials.gov registry entry for NCT05045027 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (83% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glioma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT05045027 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05045027 about?
NCT05045027 is a clinical study titled "Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma". This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between earl...
What is the current status of trial NCT05045027?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2021-09-01. Estimated completion is 2027-09-10.
What conditions does trial NCT05045027 study?
This clinical trial studies the following conditions: Glioma, Malignant Glioma, Recurrent Malignant Glioma, Recurrent Glioma.
What interventions are being tested in trial NCT05045027?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Diagnostic Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT05045027?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05045027 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
-
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
RECRUITING · Early Phase 1
-
18F-Fluciclovine PET-MRI in High-grade Glioma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
-
Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation
RECRUITING · Early Phase 1
-
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.